{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T03:12:44Z","timestamp":1788405164594,"version":"build-2803163510"},"reference-count":21,"publisher":"SAGE Publications","issue":"6","license":[{"start":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T00:00:00Z","timestamp":1778544000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Thyroid\u00ae"],"published-print":{"date-parts":[[2026,6,1]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>\n                      After progression on selpercatinib, patients with\n                      <jats:italic toggle=\"yes\">RET-<\/jats:italic>\n                      altered medullary thyroid carcinoma (MTC) face a poor prognosis. Tarlatamab\u2014a Delta-like ligand 3-targeted bispecific T-cell engager\u2014is a promising therapeutic option for patients with MTC, but a prior case series raised safety concerns in this population.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>\n                      A patient with\n                      <jats:italic toggle=\"yes\">RET-<\/jats:italic>\n                      altered MTC who progressed on selpercatinib received tarlatamab using a three-step step-up dosing regimen with modified protocols for monitoring and managing cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>This patient experienced grade 2 CRS and grade 2 ICANS after cycle 1, day 1. He did not experience any grade \u22653 treatment-related adverse events. The patient had rapid improvement of the disease-associated symptoms. After 8 weeks of treatment, the patient experienced a biochemical and radiographic complete response that is ongoing.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>A modified dosing and monitoring protocol may improve the safety of tarlatamab in patients with MTC while maintaining efficacy. Further research is needed to evaluate the role of tarlatamab in MTC.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/10507256261448706","type":"journal-article","created":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T09:38:10Z","timestamp":1778578690000},"page":"682-687","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":2,"title":["A Novel Approach to Targeting DLL3 with Tarlatamab in a Patient with Medullary Thyroid Carcinoma after Progression on Selpercatinib"],"prefix":"10.1177","volume":"36","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0709-2270","authenticated-orcid":false,"given":"Thomas J.","family":"Roberts","sequence":"first","affiliation":[{"name":"Department of Hematology\/Oncology, Massachusetts General Hospital, Boston, Massachusetts, USA."},{"name":"Harvard Medical School, Boston, Massachusetts, USA."},{"name":"Mass General Brigham Cancer Institute, Boston, Massachusetts, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine B.","family":"Meador","sequence":"additional","affiliation":[{"name":"Department of Hematology\/Oncology, Massachusetts General Hospital, Boston, Massachusetts, USA."},{"name":"Harvard Medical School, Boston, Massachusetts, USA."},{"name":"Mass General Brigham Cancer Institute, Boston, Massachusetts, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander D.","family":"Fuld","sequence":"additional","affiliation":[{"name":"Dartmouth Cancer Center, Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire, USA."},{"name":"Geisel School of Medicine at Dartmouth, Hanover, New Hampshire, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-0684-2654","authenticated-orcid":false,"given":"Aubrey","family":"Lasko","sequence":"additional","affiliation":[{"name":"Mass General Brigham Cancer Institute, Boston, Massachusetts, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew","family":"Frigault","sequence":"additional","affiliation":[{"name":"Department of Hematology\/Oncology, Massachusetts General Hospital, Boston, Massachusetts, USA."},{"name":"Harvard Medical School, Boston, Massachusetts, USA."},{"name":"Mass General Brigham Cancer Institute, Boston, Massachusetts, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katherine M.","family":"Hangar","sequence":"additional","affiliation":[{"name":"Mass General Brigham Cancer Institute, Boston, Massachusetts, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kerry","family":"Reynolds","sequence":"additional","affiliation":[{"name":"Department of Hematology\/Oncology, Massachusetts General Hospital, Boston, Massachusetts, USA."},{"name":"Harvard Medical School, Boston, Massachusetts, USA."},{"name":"Mass General Brigham Cancer Institute, Boston, Massachusetts, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter M.","family":"Sadow","sequence":"additional","affiliation":[{"name":"Harvard Medical School, Boston, Massachusetts, USA."},{"name":"Mass General Brigham Cancer Institute, Boston, Massachusetts, USA."},{"name":"Department of Pathology, Massachusetts General Hospital, Boston, Massachusetts, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lori J.","family":"Wirth","sequence":"additional","affiliation":[{"name":"Department of Hematology\/Oncology, Massachusetts General Hospital, Boston, Massachusetts, USA."},{"name":"Harvard Medical School, Boston, Massachusetts, USA."},{"name":"Mass General Brigham Cancer Institute, Boston, Massachusetts, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2026,5,12]]},"reference":[{"key":"e_1_3_5_2_1","doi-asserted-by":"publisher","DOI":"10.1210\/endrev\/bnad013"},{"key":"e_1_3_5_3_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2017.2719"},{"key":"e_1_3_5_4_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2309719"},{"key":"e_1_3_5_5_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.35.5040"},{"key":"e_1_3_5_6_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.48.4659"},{"key":"e_1_3_5_7_1","doi-asserted-by":"publisher","DOI":"10.1200\/PO.23.00053"},{"key":"e_1_3_5_8_1","doi-asserted-by":"publisher","DOI":"10.1530\/ERC-24-0224"},{"key":"e_1_3_5_9_1","doi-asserted-by":"publisher","DOI":"10.1158\/2767-9764.CRC-24-0501"},{"key":"e_1_3_5_10_1","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics17040520"},{"key":"e_1_3_5_11_1","doi-asserted-by":"publisher","DOI":"10.1530\/EC-20-0611"},{"key":"e_1_3_5_12_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2307980"},{"key":"e_1_3_5_13_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2502099"},{"key":"e_1_3_5_14_1","doi-asserted-by":"publisher","DOI":"10.1200\/OA-25-00116"},{"key":"e_1_3_5_15_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO-25-00363"},{"key":"e_1_3_5_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2018.12.758"},{"key":"e_1_3_5_17_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2024013688"},{"key":"e_1_3_5_18_1","doi-asserted-by":"publisher","DOI":"10.1177\/10781552221140320"},{"key":"e_1_3_5_19_1","doi-asserted-by":"publisher","DOI":"10.1093\/oxfordjournals.annonc.a058984"},{"key":"e_1_3_5_20_1","doi-asserted-by":"publisher","DOI":"10.1054\/bjoc.2000.1314"},{"key":"e_1_3_5_21_1","doi-asserted-by":"publisher","DOI":"10.3109\/0284186X.2016.1157264"},{"key":"e_1_3_5_22_1","unstructured":"21.NCCN clinical practice guidelines in oncology: Thyroid carcinoma (Version 1.2025). n.d. Available from: https:\/\/www.nccn.org\/guidelines\/guidelines-detail?category=1&id=1470 [Last accessed: September15 2025]."}],"container-title":["Thyroid\u00ae"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10507256261448706","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/10507256261448706","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10507256261448706","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T02:15:49Z","timestamp":1788401749000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/10507256261448706"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,12]]},"references-count":21,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,6,1]]}},"alternative-id":["10.1177\/10507256261448706"],"URL":"https:\/\/doi.org\/10.1177\/10507256261448706","relation":{},"ISSN":["1050-7256","1557-9077"],"issn-type":[{"value":"1050-7256","type":"print"},{"value":"1557-9077","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,12]]}}}